As the autoimmune T-cell engager field rapidly expands, developers face increasing pressure to demonstrate meaningful differentiation beyond simply being first to market. At the same time, regulators are grappling with how to evaluate therapies originally developed for oncology in patient populations with fundamentally different risk-benefit expectations. The challenge is no longer just proving activity, it is demonstrating why a therapy deserves adoption, investment, and regulatory approval in an increasingly competitive market.

Join biotech innovators, regulatory experts, clinical developers, and investors as they discuss how companies can successfully position their programs for both commercial and regulatory success by:

• Defining meaningful differentiation beyond target selection, exploring how developers can distinguish their therapies through safety profiles, depth and durability of response, patient convenience, biomarker strategies, co-stimulatory approaches, and disease-specific mechanisms rather than relying solely on novel targets
• Aligning development strategies with evolving regulatory expectations, discussing how regulators are approaching autoimmune T-cell engagers differently from oncology therapies, including considerations around toxicology requirements, cytokine release syndrome risk, chronic safety monitoring, and benefit-risk assessment
• Designing clinical programs that support both approval and competitive positioning, evaluating which endpoints, biomarkers, patient populations, and clinical datasets will be most important for demonstrating value to regulators, physicians, payers, and potential partners in an increasingly crowded field